Individual Study / POPCORN-COVID-19

POPCORN: COVID-19 Platform Prospective Cohort Study

POPCORN: COVID-19 Platform Prospective Cohort Study

POPCORN-COVID-19 logo
Networks -
Datasets -
Variables -
Start Year
2023
End Year
2024
Visit POPCORN-COVID-19

Members

Download
Investigators Contacts
  • Dr. Fiona Muttalib
    BC Children's Hospital
  • Dr. Stephen Freedman
    University of Calgary
  • Dr. Gita Wahi
    McMaster University Children’s Hospital
  • Dr. Shaun Morris
    Hospital for Sick Children
  • Dr. Jesse Papenburg
    Montreal Children’s Hospital
  • Dr. Bruce Wright
    Stollery Children’s Hospital
  • Dr. Ahmed Mater
    Jim Pattison Children’s Hospital
  • Dr. Darcy Beer
    The Children’s Hospital of Winnipeg
  • Dr. Rishi Ganesan
    Children's Hospital London Health Sciences Centre
  • Dr. Maala Bhatt
    Children’s Hospital of Eastern Ontario
  • Dr. Jennifer Foster
    IWK Health Centre
  • Dr. Archna Shah
    Janeway Children’s Health and Rehabilitation Centre
  • Dr. Krystel Toulouse
    CHU de Sherbrooke
  • Dr. Anupam Sehgal
    Kingston Health Sciences Centre
  • Dr. Marc-André Dugas
    CHU de Quebec l‘Universite de Laval
  • Dr. Olivier Drouin
    CHU Sainte Justine

Design

Study design
Cohort
Follow Up
* All the participants are followed up at 1 week, 2 months, 6 months and 12 months after baseline. * The follow-up "date" varies depending on the date the patient became eligible for the study.

Recruitment

Recruitment Target
  • Individuals

Number of Participants

Number of Participants
40,000
Number of Participants with Biological Samples
Supplementary Information
Target / planned size: ≈ 40,000+ participants

Access

Availability of data and biosamples

Possible Access to Data
Possible Access to Biosamples
Other

Timeline

Populations

Selection Criteria
Maximum age
17
Newborns
Twins
Countries
  • Canada
Territory
Ethnic Origin
Health Status
  • Paricipants are included in the the study if they; * Presented or admitted to a participating pediatric ED, inpatient ward, or Pediatric Intensive Care Unit. * Presented with one or more COVID-19 compatible symptoms (respiratory, febrile young infant <60 days, gastrointestinal, other). * If they tested for SARS-CoV-2 infection.
Other Criteria
Supplementary Information about selection criteria
Participants may consent to the biobank as a biobank control.

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Clinic patients
Supplementary Information
Paricipants are recruited across 16 academic pediatric institutions which are BC Children’s Hospital (Vancouver), Stollery Children’s Hospital (Edmonton), Alberta Children’s Hospital (Calgary), Jim Pattison Children’s Hospital (Saskatoon), The Children’s Hospital of Winnipeg (Winnipeg), McMaster Children’s Hospital (Hamilton), The Hospital for Sick Children (Toronto), Kingston Health Sciences Centre (Kingston), Children’s Hospital of Eastern Ontario (Ottawa), Children's Hospital London Health Sciences Centre (London), Montreal Children’s Hospital (Montreal), CHU Sainte-Justine (Montreal), CHU de Sherbrooke (Sherbrooke), CHU de Quebec l‘Université de Laval (Quebec City), Janeway Children’s Health and Rehabilitation Centre (St. John’s), and IWK Health Centre (Halifax).

Number of Participants

Number of Participants
2,000
Number of Participants with Biological Samples
Data Collection Events
# Name Description Start End
0 POPCORN-COVID-19 - SARS-CoV-2 positive Case - Baseline Information on demographics, height and weight, premature birth, SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine manufacturer, number of doses), ... 2023-01 2024-03
1 POPCORN-COVID-19 - SARS-CoV-2 positive Case - First follow-up (0 to 9 days) Information on patient status, quality of life (Pediatric Quality of Life Inventory) and disability (Functional Status Scale Survey) is collected. 2023-01 2024-03
2 POPCORN-COVID-19 - SARS-CoV-2 positive Case - Second follow-up (2 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2023-03 2024-03
4 POPCORN-COVID-19 - SARS-CoV-2 positive Case - Third follow-up (6 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2023-07 2024-03
5 POPCORN-COVID-19 - SARS-CoV-2 positive Case - Fourth follow-up (12 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2024-01 2024-03
Selection Criteria
Maximum age
17
Newborns
Twins
Countries
  • Canada
Territory
Ethnic Origin
Health Status
  • Paricipants are included in the the study if they; * Presented or admitted to a participating pediatric ED, inpatient ward, or Pediatric Intensive Care Unit. * If they tested for SARS-CoV-2 infection.
Other Criteria
Supplementary Information about selection criteria
Participants were enrolled but not matched to controls.

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Clinic patients
Supplementary Information
Paricipants are recruited across 16 academic pediatric institutions which are BC Children’s Hospital (Vancouver), Stollery Children’s Hospital (Edmonton), Alberta Children’s Hospital (Calgary), Jim Pattison Children’s Hospital (Saskatoon), The Children’s Hospital of Winnipeg (Winnipeg), McMaster Children’s Hospital (Hamilton), The Hospital for Sick Children (Toronto), Kingston Health Sciences Centre (Kingston), Children’s Hospital of Eastern Ontario (Ottawa), Children's Hospital London Health Sciences Centre (London), Montreal Children’s Hospital (Montreal), CHU Sainte-Justine (Montreal), CHU de Sherbrooke (Sherbrooke), CHU de Quebec l‘Université de Laval (Quebec City), Janeway Children’s Health and Rehabilitation Centre (St. John’s), and IWK Health Centre (Halifax).

Number of Participants

Number of Participants
No Limit
Number of Participants with Biological Samples
No Limit
Supplementary Information about selection criteria
As of September 2023, the total number of participants is 9. There is no limit to the number of participants that can be recruited for this population.
Data Collection Events
# Name Description Start End
0 POPCORN-COVID-19 - SARS-CoV-2 positive incidental Case - Baseline Information on demographics, height and weight, premature birth, SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine manufacturer, number of doses), ... 2023-01 2024-03
1 POPCORN-COVID-19 - SARS-CoV-2 positive incidental Case - First follow-up (0 to 9 days) Information on patient status, quality of life (Pediatric Quality of Life Inventory) and disability (Functional Status Scale Survey) is collected. 2023-01 2024-03
2 POPCORN-COVID-19 - SARS-CoV-2 positive incidental Case - Second follow-up (2 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2023-03 2024-03
3 POPCORN-COVID-19 - SARS-CoV-2 positive incidental Case - Third follow-up (6 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2023-07 2024-03
4 POPCORN-COVID-19 - SARS-CoV-2 positive incidental Case - Fourth follow-up (12 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2024-01 2024-03
Selection Criteria
Maximum age
17
Newborns
Twins
Countries
  • Canada
Territory
Ethnic Origin
Health Status
  • Participants are included if they tested for SARS-CoV-2 infection. Presented symptoms related other respiratory infectious syndromes (e.g., respiratory syncytial virus, influenza), febrile young infant < 60 days, gastrointestinal symptoms – including hepatitis, and others (e.g., neurological)).
Supplementary Information about selection criteria
Participants consented to the biobank only as a biobank control.

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Clinic patients
Supplementary Information
* Paricipants are recruited across 16 academic pediatric institutions which are BC Children’s Hospital (Vancouver), Stollery Children’s Hospital (Edmonton), Alberta Children’s Hospital (Calgary), Jim Pattison Children’s Hospital (Saskatoon), The Children’s Hospital of Winnipeg (Winnipeg), McMaster Children’s Hospital (Hamilton), The Hospital for Sick Children (Toronto), Kingston Health Sciences Centre (Kingston), Children’s Hospital of Eastern Ontario (Ottawa), Children's Hospital London Health Sciences Centre (London), Montreal Children’s Hospital (Montreal), CHU Sainte-Justine (Montreal), CHU de Sherbrooke (Sherbrooke), CHU de Quebec l‘Université de Laval (Quebec City), Janeway Children’s Health and Rehabilitation Centre (St. John’s), and IWK Health Centre (Halifax).

Number of Participants

Number of Participants
4,000
Number of Participants with Biological Samples
Data Collection Events
# Name Description Start End
0 POPCORN-COVID-19 - SARS-CoV-2 negative Control - Baseline Information on demographics, height and weight, premature birth, SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine manufacturer, number of doses), ... 2023-01 2024-03
1 POPCORN-COVID-19 - SARS-CoV-2 negative Control - First follow-up (0 to 9 days) Information on patient status, quality of life (Pediatric Quality of Life Inventory) and disability (Functional Status Scale Survey) is collected. 2023-01 2024-03
2 POPCORN-COVID-19 - SARS-CoV-2 negative Control - Second follow-up (2 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2023-03 2024-03
4 POPCORN-COVID-19 - SARS-CoV-2 negative Control - Third follow-up (6 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2023-07 2024-03
5 POPCORN-COVID-19 - SARS-CoV-2 negative Control - Fourth follow-up (12 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2024-01 2024-03
Selection Criteria
Maximum age
17
Newborns
Twins
Countries
  • Canada
Territory
Ethnic Origin
Health Status
  • Paricipants are included in the the study if they; * Presented or admitted to a participating pediatric ED, inpatient ward, or Pediatric Intensive Care Unit. * Diagnostic bloodwork for Myocarditis and Pericarditis was ordered or expected to be ordered based on assessment by triage or admitting teams. * Activation of a myocarditis or pericarditis clinical pathway * Another known cause for the child’s presentation determined prior to blood draw
Other Criteria
Supplementary Information about selection criteria
Participants may consent to the biobank as a biobank case.

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Clinic patients
Supplementary Information
Paricipants are recruited across 16 academic pediatric institutions which are BC Children’s Hospital (Vancouver), Stollery Children’s Hospital (Edmonton), Alberta Children’s Hospital (Calgary), Jim Pattison Children’s Hospital (Saskatoon), The Children’s Hospital of Winnipeg (Winnipeg), McMaster Children’s Hospital (Hamilton), The Hospital for Sick Children (Toronto), Kingston Health Sciences Centre (Kingston), Children’s Hospital of Eastern Ontario (Ottawa), Children's Hospital London Health Sciences Centre (London), Montreal Children’s Hospital (Montreal), CHU Sainte-Justine (Montreal), CHU de Sherbrooke (Sherbrooke), CHU de Quebec l‘Université de Laval (Quebec City), Janeway Children’s Health and Rehabilitation Centre (St. John’s), and IWK Health Centre (Halifax).

Number of Participants

Number of Participants
100
Number of Participants with Biological Samples
50
Data Collection Events
# Name Description Start End
0 POPCORN-COVID-19 - Myocarditis and Pericarditis Case - Baseline Information on demographics, height and weight, premature birth, SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine manufacturer, number of doses), ... 2023-01 2024-03
1 POPCORN-COVID-19 - Myocarditis and Pericarditis Case - First follow-up (0 to 9 days) Information on patient status, quality of life (Pediatric Quality of Life Inventory) and disability (Functional Status Scale Survey) is collected. 2023-01 2024-03
2 POPCORN-COVID-19 - Myocarditis and Pericarditis Case - Second follow-up (2 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2023-03 2024-03
4 POPCORN-COVID-19 - Myocarditis and Pericarditis Case - Third follow-up (6 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2023-07 2024-03
5 POPCORN-COVID-19 - Myocarditis and Pericarditis Case - Fourth follow-up (12 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2024-01 2024-03
Selection Criteria
Maximum age
17
Newborns
Twins
Countries
  • Canada
Territory
Ethnic Origin
Health Status
  • Paricipants are included in the the study if they; * Presented or admitted to a participating pediatric ED, inpatient ward, or Pediatric Intensive Care Unit. * Diagnostic bloodwork for Myocarditis and pericarditis was ordered or expected to be ordered based on assessment by triage or admitting teams however, an alternate diagnosis was determined, or investigations were normal.
Other Criteria
Supplementary Information about selection criteria
Participants consented to the biobank only as a biobank control.

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Clinic patients
Supplementary Information
Paricipants are recruited across 16 academic pediatric institutions which are BC Children’s Hospital (Vancouver), Stollery Children’s Hospital (Edmonton), Alberta Children’s Hospital (Calgary), Jim Pattison Children’s Hospital (Saskatoon), The Children’s Hospital of Winnipeg (Winnipeg), McMaster Children’s Hospital (Hamilton), The Hospital for Sick Children (Toronto), Kingston Health Sciences Centre (Kingston), Children’s Hospital of Eastern Ontario (Ottawa), Children's Hospital London Health Sciences Centre (London), Montreal Children’s Hospital (Montreal), CHU Sainte-Justine (Montreal), CHU de Sherbrooke (Sherbrooke), CHU de Quebec l‘Université de Laval (Quebec City), Janeway Children’s Health and Rehabilitation Centre (St. John’s), and IWK Health Centre (Halifax).

Number of Participants

Number of Participants
100
Number of Participants with Biological Samples
200
Data Collection Events
# Name Description Start End
0 POPCORN-COVID-19 - Myocarditis and Pericarditis Control - Baseline Information on demographics, height and weight, premature birth, SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine manufacturer, number of doses), ... 2023-01 2024-03
1 POPCORN-COVID-19 - Myocarditis and Pericarditis Control - First follow-up (0 to 9 days) Information on patient status, quality of life (Pediatric Quality of Life Inventory) and disability (Functional Status Scale Survey) is collected. 2023-01 2024-03
2 POPCORN-COVID-19 - Myocarditis and Pericarditis Control - Second follow-up (2 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2023-03 2024-03
4 POPCORN-COVID-19 - Myocarditis and Pericarditis Control - Third follow-up (6 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2023-07 2024-03
5 POPCORN-COVID-19 - Myocarditis and Pericarditis Control - Fourth follow-up (12 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2024-01 2024-03
Selection Criteria
Newborns
Twins
Countries
  • Canada
Territory
Ethnic Origin
Health Status
  • Paricipants are included in the the study if they; * Presented or admitted to a participating pediatric ED, inpatient ward, or PICU * Fever in last 24 hours * Activation of a MIS-C clinical pathway * Another known cause for the child’s presentation determined prior to blood draw * Diagnostic bloodwork for MIS-C was ordered or expected to be ordered based on assessment by triage or admitting teams
Other Criteria
Supplementary Information about selection criteria
Participants may consent to the biobank as a biobank case.

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Clinic patients
Supplementary Information
Paricipants are recruited across 16 academic pediatric institutions which are BC Children’s Hospital (Vancouver), Stollery Children’s Hospital (Edmonton), Alberta Children’s Hospital (Calgary), Jim Pattison Children’s Hospital (Saskatoon), The Children’s Hospital of Winnipeg (Winnipeg), McMaster Children’s Hospital (Hamilton), The Hospital for Sick Children (Toronto), Kingston Health Sciences Centre (Kingston), Children’s Hospital of Eastern Ontario (Ottawa), Children's Hospital London Health Sciences Centre (London), Montreal Children’s Hospital (Montreal), CHU Sainte-Justine (Montreal), CHU de Sherbrooke (Sherbrooke), CHU de Quebec l‘Université de Laval (Quebec City), Janeway Children’s Health and Rehabilitation Centre (St. John’s), and IWK Health Centre (Halifax).

Number of Participants

Number of Participants
300
Number of Participants with Biological Samples
150
Data Collection Events
# Name Description Start End
0 POPCORN-COVID-19 - MIS-C Case - Baseline Information on demographics, height and weight, premature birth, SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine manufacturer, number of doses), ... 2023-01 2024-03
1 POPCORN-COVID-19 - MIS-C Case - First follow-up (0 to 9 days) Information on patient status, quality of life (Pediatric Quality of Life Inventory) and disability (Functional Status Scale Survey) is collected. 2023-01 2024-03
2 POPCORN-COVID-19 - MIS-C Case - Second follow-up (2 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2023-03 2024-03
4 POPCORN-COVID-19 - MIS-C Case - Third follow-up (6 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2023-07 2024-03
5 POPCORN-COVID-19 - MIS-C Case - Fourth follow-up (12 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2024-01 2024-03
Selection Criteria
Maximum age
17
Newborns
Twins
Countries
  • Canada
Territory
Ethnic Origin
Health Status
  • Paricipants are included in the the study if they; * Presented or admitted to a participating pediatric ED, inpatient ward, or PICU * Fever in last 24 hours * Diagnostic bloodwork for MIS-C was ordered or expected to be ordered based on assessment by triage or admitting teams however, an alternate diagnosis was determined, or investigations were normal. * Another known cause for the child’s presentation determined prior to blood draw
Other Criteria
Supplementary Information about selection criteria
Participants consented to the biobank only as a biobank control.

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Clinic patients
Supplementary Information
Paricipants are recruited across 16 academic pediatric institutions which are BC Children’s Hospital (Vancouver), Stollery Children’s Hospital (Edmonton), Alberta Children’s Hospital (Calgary), Jim Pattison Children’s Hospital (Saskatoon), The Children’s Hospital of Winnipeg (Winnipeg), McMaster Children’s Hospital (Hamilton), The Hospital for Sick Children (Toronto), Kingston Health Sciences Centre (Kingston), Children’s Hospital of Eastern Ontario (Ottawa), Children's Hospital London Health Sciences Centre (London), Montreal Children’s Hospital (Montreal), CHU Sainte-Justine (Montreal), CHU de Sherbrooke (Sherbrooke), CHU de Quebec l‘Université de Laval (Quebec City), Janeway Children’s Health and Rehabilitation Centre (St. John’s), and IWK Health Centre (Halifax).

Number of Participants

Number of Participants
300
Number of Participants with Biological Samples
200
Data Collection Events
# Name Description Start End
0 POPCORN-COVID-19 - MIS-C Control - Baseline Information on demographics, height and weight, premature birth, SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine manufacturer, number of doses), ... 2023-01 2024-03
1 POPCORN-COVID-19 - MIS-C Control - First follow-up (0 to 9 days) Information on patient status, quality of life (Pediatric Quality of Life Inventory) and disability (Functional Status Scale Survey) is collected. 2023-01 2024-03
2 POPCORN-COVID-19 - MIS-C Control - Second follow-up (2 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2023-03 2024-03
4 POPCORN-COVID-19 - MIS-C Control - Third follow-up (6 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2023-07 2024-03
5 POPCORN-COVID-19 - MIS-C Control - Fourth follow-up (12 months) Information on patient status, healthcare encounters (visits and stays at the hospital/ED), SARS-CoV-2 infections (symptoms, history, testing, exposure) and vaccinations (dates, vaccine ... 2024-01 2024-03

Classifications

Socio-demographic and economic characteristics
Lifestyle and behaviours
Birth, pregnancy and reproductive health history
Perception of health, quality of life, development and functional limitations
Diseases
Symptoms and signs
Medication and supplements
Non-pharmacological interventions
Health and community care services utilization
Death
Physical measures and assessments
Laboratory measures
Cognition, personality and psychological measures and assessments
Life events, life plans, beliefs and values
Preschool, school and work life
Social environment and relationships
Physical environment
Administrative information
Cognitive functioning
Personality
Psychological distress and emotions
Other psychological measures and assessments
Perception of health
Quality of life
Life course development
Functional limitations
Other perception of health, quality of life and functional limitation-related information

Socio-demographic and economic characteristics

Age/birthdate
Sex/gender
Marital/partner status
Family and household structure
Education
Residence
Birthplace
Citizenship and immigrant status
Ethnicity, race and religion
Language
Labour force and retirement
Income, possessions, and benefits

Lifestyle and behaviours

Tobacco
Physical activity
Other and unspecified lifestyle information

Perception of health, quality of life, development and functional limitations

Quality of life
Life course development
Functional limitations

Diseases

Certain infectious and parasitic diseases (A00-B99)
Neoplasms (C00-D48)
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89)
Endocrine, nutritional and metabolic diseases (E00-E90)
Diseases of the nervous system (G00-G99)
Diseases of the circulatory system (I00-I99)
Diseases of the respiratory system (J00-J99)
Diseases of the digestive system (K00-K93)
Diseases of the skin and subcutaneous tissue (L00-L99)
Diseases of the musculoskeletal system and connective tissue (M00-M99)
Diseases of the genitourinary system (N00-N99)
Certain conditions originating in the perinatal period (P00-P96)
Injury, poisoning and certain other consequences of external causes (S00-T98)
Diseases without precise specification or falling into multiple categories

Symptoms and signs

Symptoms and signs involving the circulatory and respiratory systems (R00-R09)
Symptoms and signs involving cognition, perception, emotional state and behaviour (R40-R46)
General symptoms and signs (R50-R69)
Symptoms related to multiple categories

Medication and supplements

Medication and supplement intake
Posology and protocol of administration

Non-pharmacological interventions

Radiological interventions
Laboratory diagnosis interventions
Other and unspecified non-pharmacological interventions

Health and community care services utilization

Visits to health professionals
Hospitalizations

Death

Vital status
Cause of death

Physical measures and assessments

Anthropometry
Circulation and respiration
Other physical measures and assessments

Laboratory measures

Hematology
Biochemistry
Microbiology
Virology
Immunology
Histology
Other laboratory measures

Cognition, personality and psychological measures and assessments

Psychological distress and emotions

Physical environment

Chemical exposure
Biological exposure

Administrative information

Identifiers
Date and time-related information
Questionnaire and interview-related information
Physical and cognitive measure and biosample-related information
Data and sample collection center-related information
Other administrative information

Psychological distress and emotions

Revised Children's Anxiety and Depression Scale

Quality of life

Pediatric Quality of Life Inventory

Functional limitations

Functional Status Scale